CONSTRUCTION OF OBLIGATE VECTOR BASED ON ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) AND CONSTRUCTS FOR CANCER THERAPY Russian patent published in 2021 - IPC C12N15/869 C12N15/33 A61K48/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology. An expression vector based on herpes simplex virus type 1 (HSV-1) is proposed, containing a deletion modification in the wild-type HSV-1 genome, where the specified vector contains (i) only one copy of each of all the wild-type HSV-1 genome genes represented in two copies, (ii) only one copy of the duplicated non-coding sequences of the wild-type HSV-1 genome, and (iii) the sequences necessary for the expression of all the open reading frames (ORF) represented in one copy wild-type HSV-1 genome containing the ORF themselves and regulatory sequences, necessary for the expression of each ORF, wherein these regulatory sequences include promoters. A pharmaceutical composition for the treatment of cancer containing an effective amount of the specified recombinant oncolytic HSV-1 and a pharmacologically acceptable carrier is also proposed.

EFFECT: invention expands the arsenal of drugs for cancer treatment.

29 cl, 5 dwg, 1 tbl